Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Mer­ck has end­ed work on two sep­a­rate Phase II stud­ies of its small mol­e­cule for treat­ment-re­sis­tant de­pres­sion and mild-to-mod­er­ate Alzheimer’s dis­ease, the phar­ma con­firmed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER